Catherine Flores
YOU?
Author Swipe
View article: IMMU-56. Targeting skull-resident immuno-suppressors synergizes with immunotherapy in glioblastoma
IMMU-56. Targeting skull-resident immuno-suppressors synergizes with immunotherapy in glioblastoma Open
INTRODUCTION The immune landscape within high-grade gliomas (HGGs) has been well characterized by the field. Recent studies in neurological diseases have identified the skull/meningeal bone marrow as an immune cell reservoir, but its role …
View article: EXTH-108. Adoptive cellular therapy disrupts macrophage-derived CCL12 signaling to inhibit myeloid-derived suppressor cell migration in glioma
EXTH-108. Adoptive cellular therapy disrupts macrophage-derived CCL12 signaling to inhibit myeloid-derived suppressor cell migration in glioma Open
INTRODUCTION Our group previously developed a novel adoptive cellular therapy (ACT) platform employing polyclonal populations of tumor-reactive T cells that are efficacious against multiple models of CNS malignancies including high-grade g…
View article: Epithelial-Mesenchymal Transition Activates YAP to Drive Malignant Progression and Immune Evasion
Epithelial-Mesenchymal Transition Activates YAP to Drive Malignant Progression and Immune Evasion Open
Epithelial-mesenchymal transition (EMT) is prevalent in human cancer, and facilitates tumor metastasis and therapy resistance by enhancing cancer cell motility, invasiveness, survival, and immune evasion. However, the molecular mechanisms …
View article: EXTH-49. DEVELOPMENTAL ANTIGENS CAN TARGET EMBRYONAL PEDIATRIC BRAIN CANCERS IN ADOPTIVE CELLULAR THERAPY
EXTH-49. DEVELOPMENTAL ANTIGENS CAN TARGET EMBRYONAL PEDIATRIC BRAIN CANCERS IN ADOPTIVE CELLULAR THERAPY Open
Mutations in tumor neoantigens have shown promise in immunotherapies for many cancers, yet pediatric brain tumors, which typically have a lower mutational burden, offer fewer opportunities to capitalize on these targeted therapies. Studies…
View article: EXTH-09. GENE MODIFICATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS FOR IMPROVEMENT OF IMMUNOTHERAPIES FOR MALIGNANT GLIOMAS
EXTH-09. GENE MODIFICATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS FOR IMPROVEMENT OF IMMUNOTHERAPIES FOR MALIGNANT GLIOMAS Open
Patients living with high-grade gliomas have a poor survival prognosis. Furthermore, standard of care treatment for these malignant gliomas has not significantly improved in the past decades. Our laboratory previously demonstrated that the…
View article: EXTH-79. BREAKING THE BARRIER: ADOPTIVE CELLULAR THERAPY HALTS GLIOMA IMMUNOSUPPRESSION BY TARGETING MYELOID-DERIVED SUPPRESSOR CELL MIGRATION AND CELL CYCLE MECHANISMS
EXTH-79. BREAKING THE BARRIER: ADOPTIVE CELLULAR THERAPY HALTS GLIOMA IMMUNOSUPPRESSION BY TARGETING MYELOID-DERIVED SUPPRESSOR CELL MIGRATION AND CELL CYCLE MECHANISMS Open
INTRODUCTION Our group previously demonstrated that adoptive cellular therapy (ACT) significantly increased overall survival in mice across several brain cancer models. ACT remodels the tumor microenvironment (TME) in a pleiotropic manner,…
View article: mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors
mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors Open
Background Despite advancements in the successful use of immunotherapy in treating a variety of solid tumors, applications in treating brain tumors have lagged considerably. This is due, at least in part, to the lack of well-characterized …
View article: IMMU-14. SINGLE CELL RNASEQ OF PBMCS FROM NEWLY-DIAGNOSED GLIOBLASTOMA PATIENTS
IMMU-14. SINGLE CELL RNASEQ OF PBMCS FROM NEWLY-DIAGNOSED GLIOBLASTOMA PATIENTS Open
INTRODUCTION A multitude of recently published papers have found immunosuppression caused by glioblastoma (GBM) is not limited to the tumor microenvironment and impacts the peripheral immune system. Our group has recently reported an expan…
View article: IMMU-36. PD-1KO HEMATOPOIETIC STEM CELLS RAPIDLY DIFFERENTIATE INTO GLIOMA-INFILTRATING EFFECTOR T-CELLS
IMMU-36. PD-1KO HEMATOPOIETIC STEM CELLS RAPIDLY DIFFERENTIATE INTO GLIOMA-INFILTRATING EFFECTOR T-CELLS Open
INTRODUCTION We previously published that hematopoietic stem cell combination therapy (HSC+aPD1) extends survival in murine CNS malignancies, including glioma. To better understand lymphoid-specific mechanisms, we analyzed various lymphoid…
View article: IMMU-41. IMMUNOLOGICAL TARGETING OF SLOW-CYCLING CELLS TO PREVENT RECURRENCE IN GBM
IMMU-41. IMMUNOLOGICAL TARGETING OF SLOW-CYCLING CELLS TO PREVENT RECURRENCE IN GBM Open
Glioblastoma (GBM) is the most common primary malignancy of the central nervous system (CNS) and is typically fatal due to recurrence despite aggressive treatment. Targeting residual cells after surgical tumor removal is challenging due to…
View article: EXTH-11. ADOPTIVE CELLULAR THERAPY OVERCOMES GLIOMA IMMUNE ESCAPE BY DISRUPTING MDSC PROLIFERATION AND RECRUITMENT
EXTH-11. ADOPTIVE CELLULAR THERAPY OVERCOMES GLIOMA IMMUNE ESCAPE BY DISRUPTING MDSC PROLIFERATION AND RECRUITMENT Open
INTRODUCTION Our group has previously shown that adoptive cellular therapy (ACT) significantly extends survival in models of medulloblastoma, brain stem glioma, and glioblastoma. Further, ACT significantly decreases myeloid-derived suppres…
View article: TMIC-61. INVESTIGATING REPROGRAMING OF THE GBM’S TUMOR MICROENVIRONMENT AS A RESULT OF CO-TRANSFER OF HEMATOPOIETIC STEM CELLS (HSCS) WITH ADOPTIVE CELLULAR THERAPY
TMIC-61. INVESTIGATING REPROGRAMING OF THE GBM’S TUMOR MICROENVIRONMENT AS A RESULT OF CO-TRANSFER OF HEMATOPOIETIC STEM CELLS (HSCS) WITH ADOPTIVE CELLULAR THERAPY Open
Glioblastoma (GBM) is an incredibly aggressive and prevalent primary CNS tumor with dismal survival outcomes. GBM’s intra-tumor heterogeneity and the powerful regulatory mechanisms within the tumor microenvironment (TME) that hamper immune…
View article: 429 Divergent mechanisms of dendritic cell dysfunction in primary and adoptive cellular therapy-escaped gliomas
429 Divergent mechanisms of dendritic cell dysfunction in primary and adoptive cellular therapy-escaped gliomas Open
Background Dendritic cell (DC) plays crucial role in eliciting anti-tumor immune response through both innate and adaptive immune system. Our group has developed an adoptive cellular therapy (ACT) against high grade gliomas, which signific…
View article: GLIOMA-14 ELUCIDATING THE CELL-CELL INTERACTIONS AND GEO-SPATIAL ORIENTATION OF M2 POLARIZED MACROPHAGES/MICROGLIA WITHIN GBM'S TME AND INVESTIGATING THEIR IMMUNOSUPPRESSIVE EFFECT ON DENDRITIC CELLS
GLIOMA-14 ELUCIDATING THE CELL-CELL INTERACTIONS AND GEO-SPATIAL ORIENTATION OF M2 POLARIZED MACROPHAGES/MICROGLIA WITHIN GBM'S TME AND INVESTIGATING THEIR IMMUNOSUPPRESSIVE EFFECT ON DENDRITIC CELLS Open
Glioblastoma (GBM) is an incredibly aggressive and prevalent primary CNS tumor with dismal survival outcomes. GBM’s intra-tumor heterogeneity and lack of anti-tumor immune cell infiltration have proved to be formidable challenges to develo…
View article: IMMU-21. ELUCIDATING THE CELLULAR MECHANISMS OF THERAPEUTIC BENEFIT UNDERLYING ADOPTIVE CELLULAR THERAPY IN MODELS OF GLIOMA
IMMU-21. ELUCIDATING THE CELLULAR MECHANISMS OF THERAPEUTIC BENEFIT UNDERLYING ADOPTIVE CELLULAR THERAPY IN MODELS OF GLIOMA Open
Among pediatric cancers, malignancies of the brain carry significant morbidity and mortality, harboring dismal prognosis and poor outcomes. Our group has previously shown that adoptive cellular therapy (ACT) provides therapeutic benefit ag…
View article: Elucidating the cellular mechanisms underlying adoptive cell transfer in models of glioma
Elucidating the cellular mechanisms underlying adoptive cell transfer in models of glioma Open
Despite advances in solid tumor biology and oncology, pediatric and adult primary brain cancer and metastasis to the brain harbor dismal prognosis and poor outcomes. One avenue to overcome these clinical challenges is through developing ro…
View article: Data from Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas
Data from Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas Open
Purpose:Immunotherapy has been demonstrably effective against multiple cancers, yet tumor escape is common. It remains unclear how brain tumors escape immunotherapy and how to overcome this immune escape.Experimental Design:We studied KR15…
View article: Supplementary Table 1 and 2 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
Supplementary Table 1 and 2 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma Open
Supplementary Table 1:Tumors maintained expression of subgroup genes previously identified as unique to corresponding human MB subtypes, SHH and Group 3 tumors, respectively. Supplementary Table 2: Flow cytometric antibody panel.
View article: Supplementary Figure 6 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
Supplementary Figure 6 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma Open
Gating strategy for Ptch1 MB tumors.
View article: Supplementary Figure 5 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
Supplementary Figure 5 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma Open
Gating strategy for NSC MB Tumors.
View article: Supplementary Figure 2 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
Supplementary Figure 2 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma Open
Orthotopic transplantation maintains histological and subtype specific markers. (A) Hierarchical clustering of subtype specific genes expressed in explanted Ptch1 MB and NSC MB tumors from immunocompetent C57BL/6 hosts. (B) Transplanted Pt…
View article: Data from Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas
Data from Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas Open
Purpose:Immunotherapy has been demonstrably effective against multiple cancers, yet tumor escape is common. It remains unclear how brain tumors escape immunotherapy and how to overcome this immune escape.Experimental Design:We studied KR15…
View article: Supplementary Data from Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas
Supplementary Data from Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas Open
Supplementary Data
View article: Supplementary Figure 2 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
Supplementary Figure 2 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma Open
Orthotopic transplantation maintains histological and subtype specific markers. (A) Hierarchical clustering of subtype specific genes expressed in explanted Ptch1 MB and NSC MB tumors from immunocompetent C57BL/6 hosts. (B) Transplanted Pt…
View article: Supplementary Figure 4 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
Supplementary Figure 4 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma Open
T cell infiltration within the NSC MB tumor microenvironment does not correlate with DC infiltration.
View article: Figure S2 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma
Figure S2 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma Open
IFN-g is upregulated in the brain tumor microenvironment during T cell immunotherapy and drives HSPC differentiation into CD11c+MHCII+ DCs.
View article: Figure S9 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma
Figure S9 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma Open
IFN-g drives intratumoral HSPC differentiation.
View article: Figure S3 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma
Figure S3 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma Open
HSPCs proliferate and differentiate into antigen-presenting cells in the presence of T cell-released soluble factors.
View article: Table S1 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma
Table S1 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma Open
FACS Antibodies
View article: Figure Legend and Supplementary Figure 1 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
Figure Legend and Supplementary Figure 1 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma Open
Orthotopically transplanted tumors are uniformly lethal at determined minimum tumorigenic dose. (A) Tumors arising from Patched1 heterozygous (Ptch1+/-) mice and immune deficient NOD scid gamma (NSG) mice implanted with retrovirally transd…